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Abstract Tumour necrosis factor alpha (TNF-α) is an inflam-
matory cytokine with a wide spectrum of biological activity,
including angiogenesis. B cell activating factor (BAFF) and a
proliferation-inducing ligand (APRIL) are members of the
TNF-α family. Vascular endothelial growth factor (VEGF),
on the other hand, is one of the most characteristic pro-
angiogenic cytokines produced by multiple cell types in mul-
tiple myeloma (MM). We have analysed BAFF and APRIL
concentrations in parallel with pro-angiogenic cytokines in
serum and trephine biopsy, and the bone marrow microvascu-
lar density (MVD) in 50 patients with newly diagnosed IgG
MM and 24 healthy volunteers. The study showed statistically
higher concentrations of BAFF, APRIL and TNF-α, as well as
VEGF and its receptor, in MM patients compared to healthy
volunteers and patients in advanced stages of the disease. A
statistically positive correlation between the concentration of
TNF-α and the expression of VEGFwas demonstrated, and so
was a positive link between BAFF, APRIL, MVD and lactate
dehydrogenase (LDH). Furthermore, we observed a signifi-
cant decrease in all studied cytokines after anti-angiogenic
therapy, with meaningful differences between responders (at
least partial remission) and patients with stable disease. It was
also established that APRIL, but not BAFF, correlated with
pro-angiogenic cytokines such as VEGF with its receptor,
MVD and syndecan-1. Finally, our results showed that serum
BAFF and APRIL levels could be useful biomarkers of MM
disease activity and its progression which suggests that
APRIL could be a possible novel therapeutic target in MM.
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Introduction
Multiple myeloma (MM) is a B cell malignancy originating
from pre-switched, follicle centre B lymphocytes which dif-
ferentiate to plasma cells accumulating in the bone marrow
[1]. The crucial factors in the pathogenesis of MM include
abnormalities in angiogenesis, proliferation and apoptosis [2].
An increased or abnormal level of angiogenesis has been
considered for many years as a key feature of solid malignan-
cies and associated predominantly with the pathogenesis of
haematological diseases. Altered angiogenesis is one of the
characteristic changes in the bone marrow (BM) myeloma
microenvironment [3]. The pathophysiology of MM-induced
angiogenesis is complex and involves both direct production
of angiogenic cytokines by plasma cells and their induction
within the microenvironment. The latter are secreted by stro-
mal cells, endothelial cells and osteoclasts, and promote plas-
ma cell growth, survival and migration, as well as paracrine
cytokine secretion and angiogenesis in the bonemarrowmilieu
[4]. There is increased evidence that significantly elevated
levels of bone marrow angiogenesis in MM and several pro-
angiogenic cytokines (e.g. vascular endothelial growth fac-
tor—VEGF, basic fibroblast growth factor—bFGF, hepatocyte
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growth factor—HGF and platelet-derived growth factor—
PDGF) are present in higher concentrations in myelomatous
BM and peripheral blood and decrease after successful treat-
ment [5, 6].
Tumour necrosis factor alpha (TNF-α) is an inflammatory
cytokine with a wide spectrum of biological activity, including
angiogenesis. It influences the formation of new vessels indi-
rectly rather than by directly promoting the sprout of endo-
thelial cells and their growth. The release of angiogenic mol-
ecules (e.g. bFGF, PAF, VEGF-A and VEGF-C) and the
upregulation of proteolytic systems (e.g. uPA) are biological
events apparently triggered by TNF-α. Moreover, TNF-α has
been proved to increase the transcription of the VEGFR-2
gene in vascular endothelial cells. The upregulation of Sp-1
transcription by TNF-α appears also to lead to increased
binding of this factor to the Sp-1 binding site of the
VEGFR-2 promoter region [7, 8].
B cell activating factor (BAFF) and a proliferation-
inducing ligand (APRIL), both members of the tumour necro-
sis factor (TNF) family, represent two of the main survival
factors for immature, naive and activated B cells [9–11]. Of all
the different signalling pathways activated in MM cells by
external stimulation, the nuclear factor kappa B (NF-κB)
pathway may prove to be among the most important ones.
What is more, BAFF and APRIL, which can directly activate
the NF-κB pathway, have been identified as two of the main
survival factors for healthy plasma cells and MM cells [12,
13]. Depending on the B cell maturation stage, BAFF was
reported to induce the antiapoptotic proteins Bcl-2, A1 and
Bcl-XL and to reduce the proapoptotic protein Bak [14–16].
The not yet fully understood role of BAFF, APRIL and their
receptors in normal B cell homeostasis and in several tumour
models raises the possibility of their involvement in the path-
ogenesis of B cell malignancies. The latest research has pro-
vided evidence that myeloma cell lines and primary myeloma
cells express BAFF, APRIL and their receptors and that both
of them are myeloma cell growth factors [17]. On the other
hand, it was demonstrated that the main site of production for
BAFF and APRIL is the BM microenvironment, and it was
suggested that osteoclasts are among the predominant cell
sources for BAFF and APRIL in the MM bone marrow [18,
19]. Recently, it was demonstrated that APRIL is highly
produced by osteoclasts in MM patients [20]. BAFF binds to
three TNF receptor family members, B cell maturation antigen
(BCMA), transmembrane activator and calcium modulator
and cyclophilin ligand receptor (TACI) and BAFF receptor
(BAFF-R), whereas APRIL binds to BCMA, TACI and
heparin-sulfate proteoglycans such as syndecan-1 [19].
Syndecan-1 is not only expressed by normal plasma cells,
but it is also highly expressed by the majority of malignant
plasma cells in MM patients [21]. BAFF's ability to safeguard
myeloma cells against dexamethasone-induced apoptosis [10]
and the possible use of BAFF as a marker of disease activity
[22] have also been recently studied. Interestingly, serum
BAFF levels have been shown to serve as a useful biomarker
of MM angiogenesis [22].
The objectives of the present study were to investigate
circulating levels of APRIL and BAFF and to correlate them
with well-known parameters of disease activity, such as
TNF-α, IL-6, and syndecan-1 in parallel with pro-
angiogenic cytokines, such as VEGF with its receptor, in
serum and trephine biopsy (TB). Bone marrow microvascular
density (MVD) was taken under scrutiny, too.
Patients
Fifty patients with newly diagnosed IgGMMwere included in
the study. The median age of patients at the time of sample
collection was 61, and the range was 39–70. Twenty-eight
subjects were female and 22 were male. Patients with acute or
chronic infections, inflammatory processes and liver or kidney
diseases had been excluded from the study. Complete blood
count, erythrocyte sedimentation rate, total protein/albumin,
protein and immune electrophoresis, renal function tests and
skeletal surveys were performed in all cases. In addition, bone
marrow aspiration and biopsy samples were examined
immunohistochemically to detect plasma cells. The percent-
age of bonemarrow infiltration by plasma cells was evaluated.
At the time of diagnosis, all patients were divided into three
groups based on the International Staging System, ISS (10
patients in stage I, 14 patients in stage II and 26 patients in
stage III) (Table 1).
The patients' initial treatment ofMMdepended on their age
and comorbidities. For patients below the age of 65, the
induction regimens were thalidomide–dexamethasone and cy-
clophosphamide (CTD) prior to a monotherapy of thalido-
mide 100 mg until progression. For patients over 65 and
patients with significant concurrent illness, the standard of
care was chemotherapy with melphalan, prednisone and tha-
lidomide (MPT), followed similarly by the monotherapy of
thalidomide. Of the 50 patients, 24 were treated with CTD
combination therapy and 26 with MPT therapy. After the
treatment, patients were divided into two subgroups for fur-
ther analysis: the first numbered 34 subjects (patients with
response CR—complete remission [n =7], VGPR—very
good partial remission [n =10] and PR—partial remission
[n =17]) and the second 16 subjects (patients with SD—stable
disease). Response was assessed after six cycles of chemo-
therapy with the same methods as for diagnosis, according to
the European, International, and Autologous Bone Marrow
Transplant Registries (EBMT/IBMTR/ABMTR) criteria [23].
All patient samples, along with those from normal controls,
were collected with the approval of the ethics committee at the
Medical University of Bialystok-approved protocol with writ-
ten informed consent (agreement no. R-I-002/235/2009).
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The control group consisted of 24 age- and sex-matched
healthy volunteers.
Methods
Soluble concentration of cytokines
Quantitative assessments of cytokines were performed by
means of ELISA assays. Soluble APRIL concentrations were
measured with Human APRIL (Platinum ELISA,
eBioscience, Austria). Soluble BAFF, IL-6 and TNF-α were
evaluated using commercially available test kits
VEGF and sVEGR2 were measured using commercially
Minneapolis, MN, USA) as well.
Immunohistochemistry for syndecan-1 and for VEGF
and its receptor
Immunohistochemical examinations were conducted with
specific antibodies. Primary antibodies were used by dilution
according to the manufacturer's instructions: a dilution of 1:10
for VEGF (DakoCytomation), a dilution of 1:50 for VEGFR2
(Santa Cruz Biotechnology, Santa Cruz, CA), a dilution of
1:50 for TNF-α (Santa Cruz Biotechnology, Santa Cruz, CA)
and a dilution of 1:100 for syndecan-1, CD138 (catalogue no.
M7228, monoclonal mouse, clone Mi15, DakoCytomation).
All sections required microwave heating for receptor retrieval.
The detecting kit was LSAB+ Kits (DakoCytomation). DAB
(3,3′-diaminobenzidine) was used as a chromogen. If the
reaction was positive, brown-coloured antigen–antibody com-
plexes appeared in the position of protein receptors. The
intensity of the positive reaction was defined according to
the scale described by Kumar et al. [24]: ‘−’ indicates no
staining, ‘+’ weak staining (0–30 % plasma cells positive),
‘++’ weak to moderate staining (31–60 % plasma cells posi-
tive), and ‘+++’ strong staining (more than 60 % plasma cells
positive).
Measurement and grading of bone marrow angiogenesis
MVD was assessed in the TB samples by means of the
previously described methods used by other investigators
[25, 26]. All estimations were performed in a blinded manner.
For simple grading, slides were scanned at ×100, ×200 and
×400 magnification, and based on the extent of microvessel
staining, each slide was assigned an angiogenesis grade as
described previously: low, intermediate or high [25]. Briefly,
bone marrow TB specimens stained for CD34 were classified
as low-, intermediate- and high-grade angiogenesis, based on
the visual evaluation of the entire stained field under ×200
magnification. The assessment of low-, intermediate- and
high-grade angiogenesis was reliant primarily on the visual
impression of the number of CD34-positive microvessels
observed in the entire biopsy section. The average number
of vessels stained with CD34 was first scanned at ×100
magnification to determine three hot spots defined as areas
with the maximum number of microvessels. The hot spots
were then examined at high-powered fields (×400 magnifica-
tion) using a ×10 ocular and ×40 objective lens. Large vessels
and vessels in the periosteum or bone were excluded. Areas of
staining with no discrete breaks counted as a single vessel.
The presence of a lumen was not required.
Statistical analysis
Results were expressed as means ± standard deviation (SD).
The non-parametric Kruskal–Wallis test and one-way analysis
of variance (ANOVA) were applied to test for different stages.
Student's t test was used for a pairwise comparison of sub-
groups. Comparisons between the MM and the control groups
were performed using the non-parametric Mann–Whitney
test. Spearman's order correlation coefficient was applied to
determine links between the measured parameters. p values
below 0.05 were considered to be statistically significant.
Table 1 Clinical features of the patients
Number of patients N =50





Solitary plasmocytoma N =0
HGB [g/dl] 10.55±1.51
Serum protein [g/dl] 9.45±2.31





% Plasma cells in TB 40.43±24.64
% Plasma cells in smear BM 38.53±25.51
Creatine level [mg/dl] 0.90±0.31
PLT [×10^3] 218.40±92.53
WBC [×10^3] 5.84±2.43
The values are presented as mean ± SD
ISS International Staging System, HGB haemoglobin, Ca calcium, IgG
immunoglobulin G, β2m beta-2-microglobulin, LDH lactate dehydroge-
nase, TB trephine biopsy, BM bone marrow, PLT platelet count, WBC
white blood cells
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(Quantikine®, R&D kits, Minneapolis, MN, USA). Soluble
available test kits (Quantikine® ELISA, R&D Systems,
Results
Mean (±SD) serum values of BAFF, APRIL, IL-6, TNF-α,
VEGF and sVGFR2 are listed in Table 2. Pre-treatment my-
eloma patients had a significantly higher serum concentration
of BAFF, APRIL, VEGF, sVEGFR2, IL-6 and TNF-α com-
pared to healthy volunteers: for BAFF, TNF-α and IL-6 (p <
0.0001); for APRIL (p =0.03) and for VEGF and sVEGFR2
(p <0.01), respectively (Table 2).
For the purposes of this study, patients in stage I MM and
patients in stages II and III (according to the ISS) were
analysed separately. MM patients in advanced disease stage
III had higher serum levels of all the studied parameters in
comparison to those in stage I: for APRIL, p =0.03; BAFF,
p =0.0008; TNF-α, p =0.002; IL-6, p =0.001 and VEGF and
sVEGFR2, p =0.001, respectively. Furthermore, the study
revealed statistically significant differences in the expression
of syndecan-1, VEGF and TNF-α, p =0.003, p =0.007 and
p =0.02, respectively, in TB between stages III and I.
Meaningful dissimilarities were also found with respect to
MVD, p =0.04. Additionally, our analyses exhibited marked
differences in the concentration of BAFF, p =0.01; TNF-α,
p =0.04 and MVD, p =0.01 between stages I and II and
differences of the concentration of BAFF, p =0.002; VEGF,
p =0.01 and sVEGFR2, p =0.03 between stages II and III.
Equally worth noticing were some other statistically signifi-
cant correspondences. First of all, the concentration of all the
studied cytokines in the group of newly diagnosed MM pa-
tients differed sharply from that of patients after anti-
angiogenic regiment chemotherapy. Secondly, pronounced
differences were observed between the subgroup of patients
with PR + VGPR + CR (the first subgroup) and patients with
SD (the second subgroup). The concentrations of BAFF,
VEGF, its receptor and IL-6 (p =0.01) and APRIL (p =0.04)
and that of TNF-α, p =0.02 and expression of syndecan-1 and
MVD (p =0.01 and p =0.02) were found to be lower in the
former compared to the latter. No differences, however, were
detected in the expression of VEGF and TNF-α in TB, p >
0.05 (Table 3).
We subsequently correlated each cytokine under scrutiny
with a selection of well-known parameters of prognosis and
tumour load in MM listed in Table 1. The study demonstrated
statistically positive correspondences between the concentra-
tion of total protein and VEGF (rho=0.4, p =0.01), MVD
(rho=0.58, p =0.003), as well as TNF-α (rho=0.31, p =
0.04) and VEGF expression (rho=0.31, p =0.04). In addition,
it revealed a significantly negative correlation between the
concentration of VEGFR2 and β2m (rho=−0.34, p =0.045)
and a positive one between BAFF, APRIL, MVD and LDH,
p =0.001 and p =0.0003, p =0.02, respectively.
Apart from the abovementioned observations, our analysis
exhibited some statistically meaningful divergences between
the studied ligands. The concentration of APRIL was found to
correlate significantly and positively with the concentration of
VEGF (rho=0.54, p =0.002, Fig. 1) and IL-6 (rho=0.41, p =
0.005), and the expression of VEGF (rho=0.4, p =0.008),
syndecan-1 (rho=0.49, p =0.04, Fig. 2) and MVD (rho=
0.64, p =0.0001, Fig. 3), but not with TNF-α (rho=0.26, p =
Table 2 The mean values of chosen parameters of new diagnosed MM patients






Patients at I ISS, N =10 Patients at II ISS, N=14 Patients at III ISS, N =26
BAFF [pg/ml] 904.63±439.8 309.2±116.1* 589.09±410.6 880.69±317.9** 1,276.12±505.4***
APRIL [ng/ml] 2.69±0.4 1.59±0.41* 2.12±0.37 2.55±0.42 3.09±0.31***
TNF [pg/ml] 20.58±8.2 13.73±4.08* 16.8±3.61 21.57±6,72** 20.9±12.28***
IL-6 [pg/ml] 10.99±9.0 1.96±0.46* 8.58±4.63 9.85±4.73 12.63±10.76***
VEGF [pg/ml] 240.91±121.0 111.2±70.4* 189.7±112.4 213.78±56.52 299.78±127.05***
sVEGFR2 [pg/ml] 6,990.2±2,704.5 2,143.4±847.1* 4,883.4±1,336.5 6,460.8±1,750.7 9,225.3±1,120.9***
VEGF expression 26.09±14.8 ND 21.75.11.48 25.15±14.09 32.15±16.05***
TNF expression 11.62±7.5 ND 9.05±4.18 12.33±10.58 21.57±5.77***
MVD 19.74±6.6 ND 15.77±4.27 20.88±5.31** 22.9±8.66***
Sydecan-1 (CD138)
expression
73.12±22.9 ND 58.75±20.1 72.5±17.07 75.66±25.9***
The values are presented as mean ± SD
MM multiple myeloma, ISS International Staging System, BAFF B cell activating factors, APRIL a proliferation-inducing ligand, TNF tumour necrosis
factor, IL-6 interleukin 6, VEGF vascular endothelial growth factor, sVEGFR2 soluble vascular endothelial growth factor receptor,MVD microvascular
density, ND not done
*p <0.05 betweenMM patients and healthy volunteers; **p <0.05 between stage I and II MM patients; ***p <0.05 between stage I and III MM patients
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0.31). The study also showed a positive correlation between
the concentration of BAFF and TNF-α (rho=0.39, p =0.01)
and IL-6 (rho=0.42, p =0.008). We did find, however, a
meaningful link between the concentration of BAFF and the
expression of VEGF (rho=0.12, p =0.3), syndecan-1 (rho=
0.27, p =0.22) and MVD (rho=0.31, p =0.2). In addition, our
research revealed a positive correlation between MVD,
sVEGFR2 (rho=0.55, p =0.01) and TNF-α (rho=0.42,
p =0.04).
Discussion
Angiogenesis, the biological phenomenon of new blood ves-
sel formation, increases significantly in the bone marrow
along with a spectrum of plasma cell disorders, and becomes
a prominent feature in active MM [3]. VEGF is one of the
most characterized pro-angiogenic cytokines produced by
multiple cell types in MM [27]. VEGF acts on vascular
endothelial cells and stimulates stromal cells to produce
Table 3 The mean values of chosen parameters of MM patients before and after treatment
Cytokine No. of patients
New diagnosed patients, N =50 Patients after treatment
After the treatment, N =50 With PR + VGPR + CR, N =34 With SD, N =16
BAFF [pg/ml] 904.63±439.8 721.04±82.1* 511.21±221.3 982.2±422.02**
APRIL [ng/ml] 2.69±0.4 1.54±1.01* 1.12±0.32 2.59±1.33**
TNF [pg/ml] 20.58±8.2 15.11±4.29* 10.37±3.1 18.56±11.36**
IL-6 [pg/ml] 10.99±9.0 6.12±3.78.1* 4.93±1.07 12.6±3.19**
VEGF [pg/ml] 240.91±121.0 176.03±56.09* 134.07±54.16 245.44±43.45**
sVEGFR2 [pg/ml] 6,990.2±2,704.5 4,359.4±1,865.4* 3,942.3±1,920.1 5,129.8±3,221.9**
VEGF expression 26.09±14.8 23.12±11.3 22.5±10.4 24.01±12.4
TNF expression 11.62±7.5 9.31±5.32 8.76±4.89 9.56±5.49
MVD 19.74±6.6 11.65±4.30 9.65±3.11 13.5±4.72**
Syndecan-1 (CD138) expression 73.12±22.9 28.12±16.88* 16.22±11.3 32.32±56.1**
The values are presented as mean ± SD
MM multiple myeloma, ISS International Staging System, BAFF B cell activating factors, APRIL a proliferation-inducing ligand, TNF tumour necrosis
factor, IL-6 interleukin 6, VEGF vascular endothelial growth factor, sVEGFR2 soluble vascular endothelial growth factor receptor,MVD microvascular
density
*p <0.05 between before and after treatments of MM patients; **p <0.05 between patients with response and stable disease
Fig. 1 Correlation between
serum concentration of VEGF
and serum concentration of
APRIL in patients newly
diagnosedwith multiple myeloma
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interleukin-6, which in turn stimulates increased secretion of
VEGF and its receptors. Thus, VEGF acts as a regulator of
cellular growth, survival and migration [27]. Yet, still very
little is known about the molecular signalling pathways in-
volved in TNF-induced angiogenesis. Speculating over the
possible mechanisms, some researchers have suggested that
TNF-α directly activates endothelial cell (EC) migratory path-
ways [28] through transactivation between the endothelial/
epithelial tyrosine kinase Etk and VEGF receptor 2
(VEGFR2) [29]. TNF-α has also been reported to mediate
macrophage-induced angiogenesis [30]. The angiogenic ac-
tivity triggered by activated murine peritoneal macrophages is
completely neutralized by a polyclonal antibody to TNF-α,
implying that immunological features are common to both
TNF-α and the protein responsible for macrophage-derived an-
giogenic activity [30]. TNF-α stimulated angiogenesis in cul-
tured ECs and in cornea angiogenesis assays [28], and the
chronic expression of TNF-α at low levels in a human TNF
transgenic mice model has also been shown to induce joint
angiogenesis and inflammatory arthritis [31]. In addition,
TNF-α is known to promote angiogenesis through its ability to
synergize VEGF-induced vessel permeability, a requisite initial
event for plasma exudation and fibrin clot formation, a matrix
permissive for angiogenesis [32]. TNF-α is also capable of
Fig. 2 Correlation between
expression of syndecan-1
(CD138) and serum concentration
of APRIL
Fig. 3 Correlation between bone
marrow microvascular density
and serum concentration of
APRIL in patients newly
diagnosed with multiple
myeloma
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inducing gene expression of pro-angiogenic molecules, such as
VEGF and its receptors (VEGFRs) [7]. Indeed, the cellular
VEGF mRNA level is potently enhanced in response to
TNF-α, probably due to transcriptional activation mediated by
the transcription factor SP-1 [32], leading to the induction of a
paracrine loop for neovascularisation under pathological condi-
tions, including cancer.
In the present study, we found MM patients to have higher
serum levels of VEGF and its receptor compared to controls,
which falls in line with previous reports [33]. Even more
importantly, we confirmed the increased concentration of
VEGF and its receptor, as well as the expression of VEGF in
TB in advancing disease stages since patients in stage III had
significantly higher levels of all cytokines compared to those in
stage I. The former showed decreased values only after therapy,
with meaningful differences between the responders and pa-
tients with stable disease. In accordance with the published
data, VEGF has again transpired to be one of the angiogenesis
activators that significantly respond to successful treatment
[33]. There are, however, contradictory reports on the correla-
tion between the level of VEGF and prognosis. Mileskhin et al.
reported that high levels of VEGF were associated with re-
sponse rate in patients treated with thalidomide [34]. On the
other hand, Cibeira and collaborators have not confirmed any
correlation between the response rate and VEGF level [35].
One way or another, determining VEGF activity on the basis of
serum levels is not a reliable marker of angiogenesis as serum
VEGF is not only released by myeloma cells but also by
leukocytes and platelets during blood clotting [36]. The mea-
surement of MVD utilizing immunohistochemistry has provid-
ed an objective method for assessing the degree of neovascu-
larisation and has been shown to be a significant and indepen-
dent prognostic indicator of disease activity in various malig-
nancies including MM [4, 5]. In our study, we observed that
pre-treatment MVD of stage III patients was significantly
higher than that of stage I and II patients, and this finding
emphasizes the relevance of MVD to myeloma progression.
We also found a meaningful decrease in MVD in TB for
patients who responded to treatment. Some authors failed to
demonstrate any correlation between MVD at diagnosis and
response to initial therapy (standard chemotherapy, high-dose
therapy or thalidomide) and thus concluded that mechanisms
other than drug resistance are responsible for the prognostic
value of marrow angiogenesis [26]. In our research, we
established significant differences in MVD between patients
with at least partial response compared toMM patients who did
not respond to the anti-angiogenic therapy. In line with the
findings of one previous study [37], our results suggest angio-
genesis and primary resistance to therapy to be related features
of biologically more aggressive disease. Moreover, patients
who achieved remission after chemotherapy showed a highly
significant decrease in MVD in comparison to their pre-
treatment levels [37]. A decrease in MVD after chemotherapy
could be partly mediated by a reduction in the release of
angiogenic factors from myeloma cells and by the direct toxic
effect of the chemotherapy on ECs [38]. Still, despite the
decrease in MVD, its level still remained higher than normal
even after effective treatment [38].
Furthermore, our analyses showed a significant correlation
between MVD and LDH, which, at high levels, is a biochem-
ical marker of increased tumour mass. An increased LDH
value in newly diagnosed MM patients is a predictor of poor
prognosis that should be considered for early intensive treat-
ment [37, 38]. We also exhibited a strong link between MVD
and serum levels of TNF-α. It is worth noticing here that
previous work proved TNF-α to be a potent inducer of IL-6
production by myeloma cells and one that may play an im-
portant role in the pathogenesis of human MM [39].
To the best of our knowledge, there is no data describing
the correlation between pro-angiogenic cytokines and BAFF
and APRIL, both members of the TNF-α family which play
an important role not only in B cell development and immu-
nity but also in normal plasma cells [40]. Importantly, BAFF
can clearly stimulate the survival of plasma cells under in vitro
conditions, yet it seems superfluous in the bone marrow
in vivo. Selective local production of APRIL in the bone
marrow appears to skew the in vivo dependence of this
survival response towards APRIL. This latter idea is further
supported by a recent observation that megakaryocytes, which
produce significant amounts of APRIL [41], are a crucial
constituent of the bone marrow niche for plasma cells [42].
Therefore, such selective local production of APRIL may be
essential for the survival of lymphoid malignancies in the
bone marrow. In addition, being expressed in MM cells,
BAFF can be detected in the serum of MM patients, suggest-
ing an autocrine loop of stimulation from these tumour cells
[41]. BAFF has been reported to be secreted mainly by the
bone marrow stromal cells, and plasma cell adhesion to them
augments its secretion, resulting in NF-κB activation and
MAPK and AKT phosphorylation [10].
In the undertaken study, we found MM patients to have
higher serum levels of BAFF and APRIL compared to con-
trols, which falls in line with the previous reports [22, 43].
Furthermore, we confirmed the increased concentration of
BAFF and APRIL in advancing disease stages since patients
in stage III had significantly higher levels of both ligands
compared to those in stage I and II. Additionally, we observed
meaningful changes after anti-angiogenic treatment.
Statistical differences between patients with at least partial
remission and no responders must also be noted.
Furthermore, we found a correlation between both ligands
and LDH, which is an important prognostic variable in many
haematological malignancies [44] and, most importantly, the
growth factor IL-6, which is a pleiotropic cytokine with mul-
tiple biological activities in vitro and in vivo, including human
myeloma cell proliferation, differentiation and protection
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against drug-induced cytotoxicity [44]. Since serum levels of
IL-6 and LDH reflect the activity of MM, it is possible that the
elevated serum BAFF and APRIL concentrations found in
advanced MM stages may be related to the growth of myelo-
ma cells. This does not come as a surprise since BAFF and
APRIL are well-known stimulator factors for B cell homeo-
stasis and survival, through the activation of NF-κB pathways.
Atacicept, a specific inhibitor of BAFF and APRIL that is a
fusion protein composed of the human IgG Fc portion and the
extracellular, ligand-binding portion of the TACI receptor in
phase I study of relapsed/refractory MM or active
Waldenström's macroglobulinemia has been tried recently.
The decrease in polyclonal Ig with and bone marrow density,
myeloma cell numbers and plasma concentrations of soluble
CD138 with atacicept suggested that BAFF and APRIL may
by critical factors for the long-term survival of plasma cells. It
was also suggested that atacicept inhibits MM cell survival
within the bone marrow microenvironment [45].
It has been recently shown that the PCNA proliferative
index increases in parallel with tumour burden and correlates
with BAFF concentration inMMpatients, which suggests that
BAFF may be used as a marker of disease progression [46].
Furthermore, researchers have found a positive link between
MVD and BAFF concentration [46]. In our study, we did not
detect the association between the concentration of MVD and
BAFF. We did, however, determine a link of the second
TNF-α molecule, APRIL and MVD. In addition, our study
revealed a positive correlation between the concentration of
APRIL and VEGF and its receptor in MM patients. It also
established a link between APRIL concentration and VEGF
expression in TB. The analyses did not exhibit, however, a
significant association between VEGF with its receptor and
BAFF. The differences in our data may be due to the different
mechanisms of action between BAFF and APRIL that were
previously presented. In addition, MM cells variably express
the three specific receptors—BCMA, BAFF-R and TACI—
and express syndecan-1 as a co-receptor for APRIL and TACI,
but not for BCMA, BAFF or BAFF-R [19]. Syndecan-1 can
confer a specific bridge to mediate an APRIL-TACI loop in
the biology of primary MM cells. It was demonstrated that
MM cells can bind high amounts of APRIL and soluble TACI
through cell surface syndecan-1 and that this binding to
syndecan-1 is critical for APRIL myeloma growth and sur-
vival [47]. Our study revealed statistically significant differ-
ences in the expression of syndecan-1 and serum levels of
APRIL between stages III and I according to ISS.
Furthermore, we found a positive correlation between the
expression of syndecan-1 and APRIL and that it could en-
hance the growth and survival of MM cells.
In conclusion, our results confirmed that serum BAFF and
APRIL levels could be a useful biomarker of MM disease
activity and progression. In addition, we showed a positive
correlation between the concentrations of pro-angiogenic
cytokines: VEGF with its receptor and the concentration of
APRIL, but not BAFF. Both ligands may therefore be a novel
therapeutic target in MM.
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